WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319836
Description: Naluzotan, also known as PRX-00023, is a selective and potent 5-HT1A receptor partial agonist, for the treatment of generalized anxiety disorder and major depressive disorder. Naluzotan demonstrated significant antidepressant and anxiolytic effects as per the HAM-D and MADRS and the HAM-A, respectively, in some trials, but in others it did not. In the end it was not found to be significantly superior enough to placebo and development was stopped.
MedKoo Cat#: 319836
Name: Naluzotan (free base)
Chemical Formula: C23H38N4O3S
Molecular Weight: 450.642
Elemental Analysis: C, 61.30; H, 8.50; N, 12.43; O, 10.65; S, 7.11
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 740873-07-8(Naluzotan 2HCl)
Synonym: PRX-00023; PRX 00023; PRX00023; Naluzotan
IUPAC/Chemical Name: N-(3-(4-(4-((cyclohexylmethyl)sulfonamido)butyl)piperazin-1-yl)phenyl)acetamide
InChi Key: SPWZXWDPAWDKQE-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
SMILES Code: CC(NC1=CC=CC(N2CCN(CCCCNS(=O)(CC3CCCCC3)=O)CC2)=C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 450.642 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Brunelli SA, Aviles JA, Gannon KS, Branscomb A, Shacham S. PRX-00023, a
selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in
infant rats bred for high infantile anxiety. Pharmacol Biochem Behav. 2009
Nov;94(1):8-15. doi: 10.1016/j.pbb.2009.06.014. Epub 2009 Jul 2. PubMed PMID:
2: Mathew SJ, Garakani A, Reinhard JF Jr, Oshana S, Donahue S. Short-term
tolerability of a nonazapirone selective serotonin 1A agonist in adults with
generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008
Sep;30(9):1658-66. doi: 10.1016/j.clinthera.2008.09.006. PubMed PMID: 18840371.
3: Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, Donahue
SR, Kauffman M, Iyer GR, Reinhard JF Jr. Effects of PRX-00023, a novel, selective
serotonin 1A receptor agonist on measures of anxiety and depression in
generalized anxiety disorder: results of a double-blind, placebo-controlled
trial. J Clin Psychopharmacol. 2008 Apr;28(2):235-9. doi:
10.1097/JCP.0b013e31816774de. PubMed PMID: 18344738.
4: Iyer GR, Reinhard JF Jr, Oshana S, Kauffman M, Donahue S. Tolerability,
pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A
agonist, in healthy subjects. J Clin Pharmacol. 2007 Jul;47(7):817-24. Epub 2007
May 10. PubMed PMID: 17495280.
5: de Paulis T. Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist
for depression. Curr Opin Investig Drugs. 2007 Jan;8(1):78-86. Review. PubMed
6: Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A,
Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S. An
integrated in silico 3D model-driven discovery of a novel, potent, and selective
amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and
depression. J Med Chem. 2006 Jun 1;49(11):3116-35. PubMed PMID: 16722631.